← All trials
NCT04471064
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2020
- Primary completion
- Jul 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Jul 14, 2020
- Last posted
- Sep 22, 2020
- Enrollment
- 60
- Arms / groups
- 7 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Yiling Pharmaceutical Inc.Lead sponsor
- Proswell Medical CorporationCollaborator
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.